Research progress and coping strategy of the drug resistant mechanism of platinum anti-tumor drugs / 药学实践杂志
Journal of Pharmaceutical Practice
; (6): 302-308, 2022.
Article
en Zh
| WPRIM
| ID: wpr-935027
Biblioteca responsable:
WPRO
ABSTRACT
Platinum anti-tumor drugs are currently the most widely used first-line chemotherapeutic drugs in clinical practice, and their curative effects are remarkable. However, the problems of platinum drug resistance in non-small cell lung cancer, breast cancer, ovarian cancer and others seriously limit effectiveness and clinical application of platinum drugs. The occurrence of platinum drug resistance is caused by many factors. At present, the resistance mechanism of platinum drugs mainly includes the following aspects: decreasing the accumulation of platinum in cells, increasing the inactivation of platinum in cells, repairing DNA damage and tumor cell apoptosis inactivation. This article reviews the drug resistance mechanism and coping strategy of platinum anti-tumor drugs, providing ideas for the development of platinum anti-tumor drugs and references for overcoming clinical platinum drug resistance.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Pharmaceutical Practice
Año:
2022
Tipo del documento:
Article